www.genethique.org

Bioethic information and analysis newsletter

Previous Letter

Following Letter

N°36 - December 2002

Bioethics laws : The text from the French National Assembly is passed to the Senate 

In the context of the examination of the bioethics laws in the French Senate on 29th and 30th January 2003, N. About and F. Giraud, President and Reporter for the Commission of Social Affairs, began on 4th December to audition doctors, research scientists, religious representatives, and councillors from the Grande Loge and the Grand Orient. In order to understand what is at stake, we are publishing in parallel the text adopted on first reading at the National Assembly in January 2002 and the statement in the Senate made by J.F. Mattéi, the Minister of Health. Research on the human embryo is the centre of the debate: research using supernumerary embryos, creation of embryos for research, cloning etc... 

 
Draft law adopted at first reading by the French National Assembly on 22nd January 2002

Statement at the Senate 1
by J.F. Mattéi on 12th December 2002

Authorisation for research on the embryo
The text is intended to authorise research on supernumerary embryos which are currently frozen, (article L.2151-3), « which have been abandoned by their parental project and which are devoid of any recipient couple ». 

Authorisation to create embryos for the purpose of research 
It is not only research on supernumerary embryos which has been authorised, but also the conception of embryos for the purpose of research, as stipulated in article L.2151-2 : « In-vitro conception of human embryos for research purposes is prohibited, without prejudice to the stipulations of article L.2141-1 ». But article L.2141-1, which covers the evaluation of new MAP techniques, ends as follows : « On completion of the evaluation process, the embryos conceived through this evaluation must not be preserved, transferred, or incorporated into a research project covered by article L2151-3 ». Thus, although in-vitro conception of human embryos for research purposes is declared as prohibited, authorisation is given for the creation of embryos in order to evaluate new medically assisted procreation techniques.

Rejection of cloning
« Any practice intended to give birth to a child or to develop an embryo which is not directly descended from the gametes of a man and a woman, is prohibited ». This therefore raises the question of prohibition of reproductive cloning and so-called therapeutic cloning. 

The opening for cloning
The text of article 15 is not uninteresting. The proposed prohibition covers « any intervention » whereby the final objective is the birth of a child or the development of an embryo, without specifying its nature. This would therefore cover all acts which make a birth possible or which would enable an embryo to develop, whether in-vitro or in-vivo. During the debate on 17th January, Amendment 74 was tabled in order to prohibit even more explicitly the conception of embryos obtained by this technique. But Amendment 74 was withdrawn by the then Reporter, before being picked up again by M. Mattéi, and finally thrown out. The text adopted is therefore that which prohibits only the « development » of an embryo obtained through cloning. Articles 21 and 22 also prohibit only the « development » of a human embryo obtained through cloning. In consequence, the law does not strictly speaking prohibit the conception of an embryo, i.e. the development of a cloning technique, without subsequent development of the embryo.

Authorisation for research on the embryo
The Minister of Health does not wish to question the principle established by article 16 of the civil code which « guarantees respect for human beings from the very beginnings of life ». He considers that the embryo may only be the subject of a study if its integrity is respected and if the research is conducted in its own interests. 
Stating that medicine had always made progress through successive transgressions, he also admits that research may be undertaken on embryos conceived in-vitro in the context of medically assisted procreation (MAP) and for which there remains no "parental project". The « legitimacy » of such research will be re-examined in five years time. He explained that the therapeutic prospects of embryonic stem cells still appear a long way off, but considers that research should be pursued in parallel on embryonic cells and on adult cells, France must distinguish itself by a major commitment to research on adult stem cells.

Rejection of the creation of embryos for research 
The creation of human embryos for research purposes should remain firmly prohibited and severely punished. J.F. Mattéi considered that the possibility, introduced by the National Assembly, for the creation of embryos for the evaluation of new MAP techniques is unacceptable and incidentally contrary to article 18 of the Oviedo Convention.

Rejection of cloning
J.-F. Mattei rejects therapeutic cloning which he considers as « opening the door to reproductive cloning ». In order to prevent any temptation for reproductive cloning, he wishes to introduce in the penal code, a new crime called « Crime against the dignity of a human being », which would be aimed at reproductive cloning and eugenic practices tending towards the organisation of selection of humans.

Patents for parts of the human body
Jean-François Mattei explained that France, in order to comply with the stipulations of article 5 of European Directive 98-44/CE, must find a legal wording to avoid a patent from preventing research scientists from conducting research into new applications of molecules, genes or other parts of the human body which are already covered by a patent.

Ref : 1 Senate statement concerning the declaration by M. Mattéi, on the proposed law No.189 (2001-2002) on bioethics.

 

 

The genoma of mice and men 

On 5th December 2002 « Nature » magazine published an article announcing the sequencing of the mouse genoma. The article was signed by more than 200 authors, including Stylianos Antonarakis' team which is subsidised by the Jérôme Lejeune Foundation. This work provoked a multitude of reactions in the scientific world, because it is essential for biomedical research and for the understanding of human genetics.

A mouse model
The mouse is the best known animal from the biological point of view and is used as a model for very many diseases. Deciphering its genome will provide a better understanding of the relationship which exists between its characteristics (physiological, pathological, and physical) and its genes. But the most valuable information will be provided by comparing human and murine genetics. Because mice are used intensively in biomedical research, which produces several million individuals every year. Mice have extraordinary reproductive capacities, each female being capable of producing between 15 and 150 offspring per year ! These capabilities make for very stable lines of descent which can be modified in a controlled manner through selection or genetic manipulation. One can study the reactions in a mouse in which several examples of a given gene have been inserted or in which a gene has been deactivated (mouse KO or knock-out). Generations of mice have been created in this way, which are subject to diseases known in humans, and are then used as models for understanding the diseases and to search for treatments (cancers, obesity, hyperlipaemia, arthrosis, trisomies, etc.) : in specialised catalogues, it is possible to find several thousand types of mouse, each being a model for a different disease... Each type is perfectly identified, all its biological and phenotype constants are perfectly known. This work is considerable because, even if the creation of a mutated line of descent can cost between 30 000 and 60 000 €, the precise characterisation of a new line of descent is far more costly and can involve several years of effort. 

Mice and Men
It is remarkable to note that our distant cousin (our common ancestors date back to some 80 million years ago) is very close to us with respect to its genome and its workings. Before it can help us to understand the function of each gene, the mere sequencing of its genome is already providing invaluable information:
- the murine genome is slightly smaller (14 %) than the human genome..
- more than 90 % of the two genoma correspond to regions relating to genes performing the same functions and in the same order. This order seems important for the working of the genome and is probably not as it is merely by chance.
- there are 60 % of differences between the genoma with respect to the 4 bases, ATGC (elementary units for which the order has been identified by sequencing). The speed of changes to these bases in evolution is twice as fast in mice.
- 80 % of murine genes have a gene which is orthologous with man. Only 1 % of murine genes have no equivalent in humans and there are many analogies between the two species regarding their systems and their functioning.

Junk ADN, not so junk ...
The proportion of identical genoma between mice and humans is greater than expected and does not merely cover the protein coding genome (genes). For the portions which are not coding for proteins, the ADN known in certain circles as junk ADN, seems too be of great significance. It constitutes the majority of the genome, 90 % in humans. For example, the human chromosome 21 has a very small number of genes. These genes are located in mice on chromosomes 16, 17 and 10. The human chromosome 21 has been considered as a desert from the point of view of genes, with only 240 genes and very broad bands of non coding ADN. These broad non coding bands are retained in the corresponding zones in mice, thus showing the importance of this ADN whose function remains to be understood.

The continuous and rapid progress in the field of genomics is therefore making research scientists ever more optimistic about discovering, alongside genic therapy, new therapeutic paths, including for chromosomic diseases such as Trisomy 21.

 

  is a monthly newsletter, distributed free of charge, and published by the Jérôme Lejeune Foundation. Director of the Publication and Editor in chief : Jean-Marie Le Méné 
Contact : Aude Dugast - 31 rue Galande - 75005 Paris - France - Tel : +33 (0)1.55.42.55.14 - ISSN 1638-198 X
contact@genethique.org